Purtscher retinopathies: Are we aiming at the wrong target?

Yusuf, Imran H.; Sl, Watson

doi:10.1038/eye.2013.47

Cited by 7 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, this patient developed Purtscher-like retinopathy while on systemic corticosteroids, albeit at a low dosage. It has been suggested that corticosteroids may be inefficient in cases of Purtscher-like retinopathy that are primarily triggered by thrombotic microangiopathy, such as in aHUS [ 58 ]. Solely targeting the inflammatory component will not affect microembolization since other complex pathogenic events such as hemostasis, thrombosis and complement dysregulation will remain unanswered [ 58 ].…”

Section: Discussionmentioning

confidence: 99%

Reversal of threatening blindness after initiation of eculizumab in Purtscher-like retinopathy secondary to atypical hemolytic uremic syndrome

et al. 2017

View full text Add to dashboard Cite

Purtscher-like retinopathy, a rare manifestation of systemic thrombotic microangiopathy, is a potentially visually debilitating condition with no effective proven treatment. Distinct pathogenic pathways have been proposed as etiological factors. We revisit the etiology of Purtscher-like retinopathy based on the rapid response and profound visual improvement after initiation of systemic intravenous eculizumab, an inhibitor of the complement cascade, in a patient with Purtscher-like retinopathy secondary to familial atypical hemolytic uremic syndrome (aHUS) due to a mutation in complement factor H. We hypothesize that the efficacy of eculizumab in this patient provides evidence for pathogenic events in the retina similar to those encountered in the renal microvasculature of aHUS patients, namely complement-mediated thromboembolization as a result of activation of the complement cascade in endothelial cells with release of tissue factor and development and amplification of a procoagulant state. To the best of our knowledge, this is the first report in the literature of eculizumab as an effective therapeutic strategy in Purtscher-like retinopathy.

show abstract

Section: Discussionmentioning

confidence: 99%

Reversal of threatening blindness after initiation of eculizumab in Purtscher-like retinopathy secondary to atypical hemolytic uremic syndrome

et al. 2017

View full text Add to dashboard Cite

show abstract

Purtscher-like retinopathy associated with squamous cell carcinoma of the cervix

2017

View full text Add to dashboard Cite

This case serves as the first report of Purtscher-like retinopathy secondary to acute renal failure associated with cervical carcinoma, expanding the list of causes of Purtscher's or Purtscher-like retinopathies. In the presence of significant uremia and absence of previously known association, the authors postulate that the sudden surge of uremia causes increase of endothelin-1 (a potent vasoconstrictor), resulting in downstream endothelin-induced vasculopathy with subsequent occlusion of the pre-capillary arteriolar network.

show abstract

Pseudo-syndrome de Purtscher après mise en place d’une prothèse de voie biliaire

Gonzalvez

Darrason

Donnadieu

et al. 2018

Journal Français d'Ophtalmologie

View full text Add to dashboard Cite

Purtscher retinopathies: Are we aiming at the wrong target?

Cited by 7 publications

References 7 publications

Reversal of threatening blindness after initiation of eculizumab in Purtscher-like retinopathy secondary to atypical hemolytic uremic syndrome

Reversal of threatening blindness after initiation of eculizumab in Purtscher-like retinopathy secondary to atypical hemolytic uremic syndrome

Purtscher-like retinopathy associated with squamous cell carcinoma of the cervix

Pseudo-syndrome de Purtscher après mise en place d’une prothèse de voie biliaire

Contact Info

Product

Resources

About